Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

If you don’t know what Fibonacci day is then go now and have a look at the calendar, write today’s date in the Month/Day format (11/23), you’ll notice a pattern, the first four digits of the famous ...

This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Who doesn’t love a good math holiday? Most people know about Pi ...

While the bears dominated price action early last week, the bulls managed to show strong support below $100,000. Bitcoin price dropped briefly below $100,000 on Tuesday, Wednesday, and Friday, but ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...